References
- LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
- Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833
- NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with anti-psychotic medication in the outpatient treatment of schizophreniaPsychiatry Res20101762–310911320185182
- Alvarez-JimenezMPriedeAHetrickSERisk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studiesSchizophr Res20121391–311612822658527
- MacfaddenWMaYWThomas HaskinsJBossieCAAlphsLA prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophreniaPsychiatry20107112331
- RosenheckRAKrystalJHLewRLong-acting risperidone and oral antipsychotics in unstable schizophreniaN Engl J Med2011364984285121366475
- PietriniFD’AnnaGTatiniLChanges in attitude towards LAI antipsychotic maintenance treatment: a two-year follow-up studyEur Psychiatry201853586529957369
- KishimotoTHagiKNittaMEffectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studiesSchizophr Bull201844360361929868849
- CheungSHamuroYMahlichJNakaharaTSruamsiriRTsukazawaSDrug utilization of Japanese patients diagnosed with schizophrenia: an administrative database analysisClin Drug Investig2017376559569
- KishimotoTSanghaniSRussMJIndications for and use of long-acting injectable antipsychotics: consideration from an inpatient settingInt Clin Psychopharmacol201732316116828181959
- JaegerMRosslerWAttitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatristsPsychiatry Res20101751–2586220004980
- TsangHWFongMWFungKMChungRCPerceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): psychiatrists versus patients in Hong KongInt J Psychiatry Clin Pract2010141233224917229
- FujiiYIwataNTakahashiKLarge-scale about psychiatrists’ use, knowledge and attitudes to depot antipsychotics: a comparison between Japanese and German psychiatristJpn J Clin Psychpharmacol201215797810
- PatelMXde ZoysaNBernadtMBindmanJDavidASAre depot antipsychotics more coercive than tablets? The patient’s perspectiveJ Psychopharmacol201024101483148919304865
- FourrierAGasquetIAllicarMPBouhassiraMLépineJPBégaudBPatterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatristsBr J Clin Pharmacol2000491808610606841
- BarnesTRShingleton-SmithAPatonCAntipsychotic long-acting injections: prescribing practice in the UKBr J Psychiatry Suppl200952s37s4219880915
- WilliamsRKopalaLMallaASmithGLoveLBalshawRMedication decisions and clinical outcomes in the Canadian national outcomes measurement study in schizophreniaActa Psychiatrica Scandinavica2006113s4301221
- WestJCMarcusSCWilkJCountisLMRegierDAOlfsonMUse of depot antipsychotic medications for medication nonadherence in schizophreniaSchizophr Bull2008345995100118093962
- InadaTInagakiAPsychotropic dose equivalence in JapanPsychiatry Clin Neurosci201569844044725601291
- BusnerJTargumSDThe clinical global impressions scale: applying a research tool in clinical practicePsychiatry2007472837
- InadaTEvaluation and diagnosis of drug-induced extrapyramidal symptomsYagiGCommentary on the DIEPSS and Guide to Its UsageTokyoSeiwa Publishers19961160
- AasIHGuidelines for rating global assessment of functioning (GAF)Ann Gen Psychiatry2011101221251305
- WareJESherbourneCDThe MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selectionMed Care19923064734831593914
- TaftCKarlssonJSullivanMDo SF-36 summary component scores accurately summarize subscale scores?Qual Life Res200110539540411763202
- RosenbergMSociety and the Adolescent Self-ImagePrinceton University PressPrinceton1965
- HeresSSchmitzFSLeuchtSPajonkFGThe attitude of patients towards antipsychotic depot treatmentInt Clin Psychopharmacol200722527528217690596
- KimSWLeeYHJangJEComparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patientsInt Clin Psychopharmacol2013282808623325306
- PatelMXde ZoysaNBernadtMDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: depot versus oralJ Clin Psychiatry200869101548155619192437
- PatelMXde ZoysaNBernadtMDavidADepot and oral anti-psychotics: patient preferences and attitudes are not the same thingJ Psychopharmacol200923778979618583438
- CastleDMorganVJablenskyAAntipsychotic use in Australia: the patients’ perspectiveAust N Z J Psychiatry200236563364112225447
- RobertsLWGeppertCMEthical use of long-acting medications in the treatment of severe and persistent mental illnessesCompr Psychiatry200445316116715124145
- IyoMNakagomeKWakamatsuATakahashiKFact-finding survey on awareness and utilization of depot antipsychotics for schizophrenia-results of questionnaire survey of psychiatric nurses and schizophrenia patients in terms of relapse prevention and medicationJap J Psychiatry20141915562
- DivacNProstranMJakovcevskiICerovacNSecond-generation antipsychotics and extrapyramidal adverse effectsBiomed Res Int20142014916
- LeuchtSKaneJMKisslingWHamannJEtschelEEngelRRWhat does the PANSS mean?Schizophr Res2005792–323123815982856
- KirschnerMTheodoridouAFusar-PoliPKaiserSJägerMPatients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosisTher Adv Psychopharmacol201332899924167680